Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Haleon PLC Sponsored ADR (HLN) vs Takeda Pharmaceutical Co. (TAK)

Haleon PLC Sponsored ADR and Takeda Pharmaceutical Co. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $59.2B against $40.3B — 1.5× the size. Haleon PLC Sponsored ADR trades at the lower P/E: 20.6× against 28.4×. Haleon PLC Sponsored ADR has the higher net margin (13.8% vs 7.12%) and the lower return on invested capital (0.00% vs 2.88%). Both pay a dividend; Takeda Pharmaceutical Co. yields more (4.52% vs 1.70%). Across the 22 metrics below, Takeda Pharmaceutical Co. leads on 12 and Haleon PLC Sponsored ADR on 10.

Valuation

Metric HLN TAK Drug Manufacturers Specialty & Generic median
P/E 20.64 28.36 20.14
P/S 2.35 1.99 2.25
P/B 1.93 1.25 1.90
Price to free cash flow 9.36 8.03 16.54
EV/EBITDA 12.36 10.48 12.29
EV/Sales 2.90 2.91 2.56
Earnings yield 4.84% 3.53% (2.99%)
Free cash flow yield 10.68% 12.46% 0.00%

Profitability

Metric HLN TAK Drug Manufacturers Specialty & Generic median
Gross margin 62.22% 65.85% 53.94%
Operating margin 17.93% 11.61% 0.00%
Net margin 13.79% 7.12% 0.00%
Free cash flow margin 0.00% 24.74% 0.00%
Return on equity 0.00% 4.42% (0.40%)
Return on assets 0.00% 2.15% (3.32%)
Return on invested capital 0.00% 2.88% 0.00%

Growth

Metric HLN TAK Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 0.66% 10.01%
EPS growth (last fiscal year) 22.50% (244.86%) —
Revenue growth, 5-year CAGR 1.43% (0.21%) 6.74%
Net income growth, 5-year CAGR 6.98% 0.00% 0.00%

Health

Metric HLN TAK Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.65 0.05
Current ratio 0.69 1.14 2.31
Net debt to EBITDA 2.63 5.84 0.85

Dividend

Metric HLN TAK Drug Manufacturers Specialty & Generic median
Dividend yield 1.70% 4.52% 1.70%
Payout ratio — 0.50 0.00

Size

Metric HLN TAK Drug Manufacturers Specialty & Generic median
Market cap 40.28b 59.16b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack